• In late February 2026, ADMA Biologics reported fourth-quarter 2025 sales of US$139.16 million and full-year 2025 sales of US$510.17 million, alongside lower year-on-year net income and earnings per share, while reiterating revenue guidance for 2026 and 2027 and announcing CFO and Treasurer succession from Brad Tade to Terry Kohler.
• ADMA also continued returning capital to shareholders through buybacks and a large 2026 repurchase initiative, signaling management’s confidence in its cash generation and long-term business outlook despite earnings compression.
• Next, we’ll examine how ADMA’s sizeable 2026 share repurchase plan and capital return focus affects the existing investment narrative.

Find 50 companies with promising cash flow potential yet trading below their fair value.

ADMA Biologics Investment Narrative Recap

To own ADMA Biologics, you need to believe its focused plasma-derived portfolio and yield-enhanced manufacturing can support durable revenue growth despite earnings volatility. The latest results, with higher 2025 sales but lower net income, keep the near term focus on margin execution while reinforcing that dependence on a narrow immunoglobulin franchise and operational risks at Boca Raton remain the key overhangs. The news does not fundamentally change those core risks or the main commercial ramp catalyst.

The most relevant update here is the reaffirmed 2026 and 2027 revenue guidance, with management still targeting more than US$635 million and more than US$775 million respectively. That continuity, alongside the new CFO and Treasurer appointment, keeps attention on whether ADMA can translate its yield enhancement process and plasma network into sustained margin improvement, which remains central to the bullish thesis but also to concerns about execution risk if scale up or collection conditions worsen.

Yet behind the upbeat guidance, investors should also be aware that if plasma supply tightens or input costs spike...

ADMA Biologics' narrative projects $904.6 million revenue and $350.9 million earnings by 2028. This requires 24.0% yearly revenue growth and about a $142 million earnings increase from $208.9 million today.

Uncover how ADMA Biologics' forecasts yield a $27.25 fair value, a 77% upside to its current price.

Exploring Other Perspectives

Before this news, the most optimistic analysts were banking on about US$980.7 million of revenue and US$372.2 million of earnings by 2028, which is a far more upbeat path than consensus and could be tested if rising plasma input costs or supply constraints start to bite.

Explore 10 other fair value estimates on ADMA Biologics - why the stock might be worth just $17.00!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your ADMA Biologics research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free ADMA Biologics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ADMA Biologics' overall financial health at a glance.

Searching For A Fresh Perspective?

Our top stock finds are flying under the radar-for now. Get in early:

• Uncover the next big thing with 30 elite penny stocks that balance risk and reward.
• Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• We've uncovered the 16 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.